Mazdutide - 10mg

Mazdutide - 10mg

10mg of lyophilized product in a 3ml vial

This product needs to be reconstituted before use

Mazdutide, an investigational therapeutic agent, is currently under research for its potential efficacy in treating type 2 diabetes mellitus (T2DM) and obesity. This dual-receptor agonist targets both the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor, aiming to provide a comprehensive approach to metabolic regulation.

Components

Mazdutide is designed as a single molecular entity that combines the activities of a GLP-1 receptor agonist and a glucagon receptor agonist.

• GLP-1 Receptor Agonist:
• Biological Function: Mimics the incretin hormone GLP-1.
• Mechanism of Action: Enhances glucose-dependent insulin secretion, inhibits glucagon release, delays gastric emptying, and promotes satiety. These actions collectively contribute to improved glycemic control and weight loss.
• Glucagon Receptor Agonist:
• Biological Function: Mimics the hormone glucagon.
• Mechanism of Action: Stimulates hepatic glucose production, increases energy expenditure, and potentially reduces body weight by promoting lipolysis and thermogenesis.

Combined Mechanism of Action

Mazdutide leverages the dual action of GLP-1 and glucagon receptor agonism to achieve metabolic benefits:

• GLP-1 Receptor Agonism: By enhancing insulin secretion in response to elevated blood glucose levels and suppressing glucagon release, mazdutide helps to lower blood glucose levels. The delayed gastric emptying and increased satiety contribute to reduced caloric intake and weight loss.
• Glucagon Receptor Agonism: This component stimulates hepatic glucose production, which helps to maintain energy balance. It also promotes increased energy expenditure and fat oxidation, contributing to weight reduction and improved metabolic health.

Clinical Implications

 The dual agonist approach of mazdutide offers several potential therapeutic advantages for patients with T2DM and obesity:

• Enhanced Glycemic Control: The combined effects on insulin and glucagon secretion result in better regulation of blood glucose levels.
• Weight Loss: The synergistic actions on appetite suppression, increased energy expenditure, and fat oxidation lead to significant weight reduction, which is crucial for managing T2DM and reducing associated comorbidities.
• Metabolic Health: The dual receptor agonism supports overall metabolic health by addressing both glucose homeostasis and energy balance.

Research and Development

Ongoing clinical trials are evaluating the safety, efficacy, and pharmacokinetics of mazdutide. Early data suggest that this dual-receptor agonist has the potential to offer substantial benefits in terms of glycemic control and weight loss. Further studies are required to confirm these findings, explore long-term outcomes, and determine the optimal dosing regimen.

MAZDUTIDE is intended for research or lab use only and is not approved for any form of in vivo use. Please read and adhere to our terms and conditions before ordering.